The SMART Hub is a collection of researchers, engineers, and economic and policy experts looking to “enact a paradigm shift in the use and management of the wireless spectrum.” Photo via Getty Images

The University of Houston has signed on to be a part of an organization that is working toward next-gen technology for defense purposes.

UH has announced its partnership with the Department of Defense Spectrum Innovation Center’s Spectrum Management with Adaptive and Reconfigurable Technology (SMART) Hub, which aims to conduct spectrum research to help with national defense needs. SMART Hub will develop next-generation technologies, and the research team will contribute expertise in spectrum security, economics, communication systems, radar, circuits, policy, and more.

The center is led by Baylor University, and is a collection of researchers, engineers, and economic and policy experts looking to “enact a paradigm shift in the use and management of the wireless spectrum” according to SMART Hub. The consortium is worth $5 million, and comes after UH recently awarded its largest grant in history—$63.5 million from the U.S. DoD. The previous DoD contract aims to support the campus in developing analytical modeling and simulation platforms for the U.S. Army.

Growth in use of electronic devices has led to the jamming of the bandwidth available in the wireless spectrum (radio, TV, wireless phone signals). SMART Hub will focus on new approaches of spectrum communication to assist military and corporate organizations that will confront this issue more than before. SMART Hub will combine efforts of 29 researchers at 17 institutions.

“We will be working on groundbreaking technology that will revolutionize how we use the spectrum,” professor of electrical and computer engineering at Baylor and director of the efforts Charles Baylis said in a news release. “Rather than fixed systems that use the same frequency and stay there, we’re designing systems that can adapt to their surroundings and determine how to successfully transmit and receive. It’s a true paradigm shift that requires the type of collaboration we will have in SMART Hub.”

UH’s SMART Hub team, which will be tasked to produce strategies for enhanced communication in challenging spaces like regions having electromagnetic interference, forests, inner city environments, or mountainous terrains, includes:

  • David Jackson, professor of electrical and computer engineering
  • Zhu Han, Moores Professor of electrical engineering
  • Daniel Onofrei, associate professor of mathematics

From left, the UH SMART Hub team includes: Daniel Onofrei, associate professor of mathematics; David Jackson, professor of electrical and computer engineering; and Zhu Han, Moores Professor of electrical engineering.

The UH software will help DrillDocs customers make better and safer decisions out on the rigs. Photo via Getty Images

Startup taps UH-licensed technology to better optimize rig analytics

here's the drill

A Houston startup has tapped into the know-how of three University of Houston professors to help improve oil and gas drilling operations.

The startup, DrillDocs, has licensed software developed by UH professors Jiefu Chen, Xuqing (Jason) Wu, and Zhu Han that enables real-time analysis of activity at onshore and offshore drilling rigs. Specifically, the software examines video to help classify the volume of cuttings from the shale-shaker components of drilling equipment.

According to the American Association of Petroleum Geologists, cuttings are small pieces of rock that are chipped away by a bit while a well is being drilled. The fragments then travel from the bit to the surface of the water, where they can be "caught" and studied. Drill cuttings often yield the only rock data gained from a well.

"Cutting analysis is an important task for an efficient, low-cost, and risk-free drilling execution," Chen says in a UH news release.

According to the news release, the UH software will study the cutting data to help DrillDocs customers "make more informed drilling decisions, reduce safety and environmental risks, and improve drilling performance and production."

Drilling technicians usually must repeatedly study cuttings manually, which can stifle progress and lead to human errors, according to UH.

Calvin Holt and Francois Ruel co-founded DrillDocs in 2020. The bootstrapped startup is developing the CleanSight system, which monitors shale-shaker components in an effort to reduce drilling costs and risks. DrillDocs' surface-based computer vision system can deliver data via laptops, smartphones, and other devices about the size, shape, and quantity of rocks floating to the surface.

In March, DrillDocs was identified as one of the four most promising startups that participated in a CERAWeek pitch competition.

"We're taking computer vision to the drilling rig," Holt, CEO of DrillDocs, said during his pitch. "Now, for the first time, drilling and geomechanics teams will have unique, real-time data to ascertain the well's condition."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”